GLAND - Technical Analysis with Chart Patterns & Indicators
Back to ListTechnical Rating: 3.7
| Stock Code | GLAND | Market Cap | 27,493 Cr. | Current Price | 1,670 ₹ | High / Low | 2,131 ₹ |
| Stock P/E | 23.2 | Book Value | 610 ₹ | Dividend Yield | 1.08 % | ROCE | 15.8 % |
| ROE | 11.6 % | Face Value | 1.00 ₹ | DMA 50 | 1,748 ₹ | DMA 200 | 1,778 ₹ |
| Chg in FII Hold | -0.32 % | Chg in DII Hold | 0.36 % | PAT Qtr | 326 Cr. | PAT Prev Qtr | 302 Cr. |
| RSI | 40.2 | MACD | -44.1 | Volume | 2,24,824 | Avg Vol 1Wk | 1,71,166 |
| Low price | 1,200 ₹ | High price | 2,131 ₹ | PEG Ratio | -6.75 | Debt to equity | 0.00 |
| 52w Index | 50.5 % | Qtr Profit Var | 10.4 % | EPS | 71.0 ₹ | Industry PE | 27.6 |
📊 Chart & Trend: GLAND is trading at ₹1,670, below both its 50 DMA (₹1,748) and 200 DMA (₹1,778), reflecting short-term weakness. RSI at 40.2 suggests the stock is nearing oversold territory, while MACD (-44.1) indicates bearish momentum. Bollinger Bands show price leaning toward the lower band, signaling pressure but potential for stabilization.
📈 Momentum Signals: Volume (2.24L) is higher than the 1-week average (1.71L), showing increased activity despite weakness. RSI near 40 suggests caution but also hints at accumulation opportunities.
💡 Entry Zone: ₹1,630–₹1,660 (support zone).
🚪 Exit Zone: ₹1,740–₹1,780 (resistance). A breakout above ₹1,780 could open room toward ₹1,850.
📌 Trend Status: The stock is currently consolidating with bearish bias after correcting from its high of ₹2,131, showing sideways-to-downward movement around key averages.
Positive
- Debt-free balance sheet (0.00 debt-to-equity).
- EPS of ₹71.0 reflects solid profitability.
- Quarterly PAT growth (₹326 Cr vs ₹302 Cr) shows earnings momentum.
- DII holdings increased (+0.36%), signaling domestic institutional support.
Limitation
- ROCE (15.8%) and ROE (11.6%) are moderate compared to sector leaders.
- Stock trading below both 50 DMA and 200 DMA reflects technical weakness.
- Negative PEG ratio (-6.75) suggests valuation concerns relative to growth trajectory.
Company Negative News
- Decline in FII holdings (-0.32%) indicates reduced foreign investor confidence.
- Stock corrected significantly from its 52-week high of ₹2,131, showing volatility.
Company Positive News
- Quarterly profit growth of 10.4% supports earnings strength.
- Strong book value (₹610) provides margin of safety.
- Dividend yield of 1.08% adds income appeal.
Industry
- Pharmaceutical sector enjoys steady demand and global growth opportunities.
- Industry PE (27.6) is slightly above GLAND’s P/E (23.2), suggesting relative undervaluation.
- Peers trade at premium valuations, positioning GLAND as a potential value play.
Conclusion
⚖️ GLAND is in a consolidation phase with bearish undertones. Fundamentals remain stable (debt-free, strong book value, EPS growth), but technical signals suggest caution in the short term. Entry near ₹1,630–₹1,660 offers a margin of safety, with exits around ₹1,740–₹1,780. Long-term investors may hold for sector strength and valuation comfort, while traders should wait for a breakout above ₹1,780 for momentum trades.
Selva, would you like me to extend this into a basket overlay with peer benchmarking against pharma majors like Divi’s Lab, Biocon, and Sun Pharma? That would highlight relative strength and rotation opportunities across the pharmaceutical sector.